The latest edition of the PCORI Emerging Health Care Innovation Brief features FDA approval of a treatment for narcolepsy Type 1 and an accelerated approval of a treatment for cutaneous melanoma, a form of skin cancer.
Other topics include:
◻️ BCB-276, a chimeric antigen receptor (CAR) T-cell therapy designed to treat a rare, aggressive pediatric brain tumor
◻️ Centanafadine (Simtriyo), a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor and central nervous system stimulant to treat attention-deficit/hyperactivity disorder in children and adults
Read more:
pcori.me/4ilTv9J